ConductScience.org, home

Paper17567869

Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.

Isaacs KL and 10 others. Inflamm Bowel Dis, 2007. Cited by 90 papers, by iCite.

Cite this record

ConductScience Library. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Papers, record 17567869. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17567869

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.
PubMed
Journal
Inflamm Bowel Dis
PubMed
Year
2007
PubMed
Publication types
Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
90
iCite
Relative citation ratio, by iCite
2.77
iCite
Revised in PubMed
2018-12-01
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Isaacs KLKim L
2Sandler RSRobert S
3Abreu MMaria
4Picco MFMichael F
5Hanauer SBStephen B
6Bickston SJStephen J
7Present DDaniel
8Farraye FAFrancis A
9Wolf DDouglas
10Sandborn WJWilliam J
11Crohn's and Colitis Foundation of America Clinical AllianceGroup

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Infective AgentsMajor topic
PouchitisMajor topic
RifamycinsMajor topic
Acute Disease
Administration, Oral
Adult
Chronic Disease
Dose-Response Relationship, Drug
Double-Blind Method
Endoscopy, Gastrointestinal
Female
Follow-Up Studies
Humans
Male
Pilot Projects
Remission Induction
Retrospective Studies
Rifaximin
Severity of Illness Index
Treatment Outcome

Source PubMed

Download CSV of topics

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT06312683Rifaximin for the Secondary Prevention of Recurrent PouchitisBackgroundClinicalTrials.gov
NCT06864403Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the PouchBackgroundClinicalTrials.gov
NCT07756359Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)BackgroundClinicalTrials.gov

Download CSV of trials

Cited by43

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 90 citations.

PMIDTitleJournalYearIn PapersSource
42739016The Gut Microbiome in Pouchitis: A Narrative Review of Pathogenesis and Therapeutic Modulation.Nutrients2026https://conductscience.org/library/papers/42739016PubMed
41884160Optimal Antibiotic Selection for the Treatment of Pouchitis After Ileal Pouch-Anal Anastomosis.J Inflamm Res2026https://conductscience.org/library/papers/41884160PubMed
40515946Managing Pouchitis: Where do Antibiotics End, and Advanced Therapies Begin?Curr Gastroenterol Rep2025https://conductscience.org/library/papers/40515946PubMed
39948209A rifamycin SV in situ gelling formulation for the treatment of pouchitis.Drug Deliv Transl Res2025https://conductscience.org/library/papers/39948209PubMed
39466277Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders-A Systematic Review and Meta-Analysis.Am J Gastroenterol2025https://conductscience.org/library/papers/39466277PubMed
39334930Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand.Biomolecules2024https://conductscience.org/library/papers/39334930PubMed
38929596Diagnosis and Medical Treatment of Acute and Chronic Idiopathic Pouchitis in Inflammatory Bowel Disease.Medicina (Kaunas)2024https://conductscience.org/library/papers/38929596PubMed
38664536Pouchitis: pathophysiology and management.Nat Rev Gastroenterol Hepatol2024https://conductscience.org/library/papers/38664536PubMed
38128971AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders.Gastroenterology2024https://conductscience.org/library/papers/38128971PubMed
37971270The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.Clin Microbiol Rev2023https://conductscience.org/library/papers/37971270PubMed
37815701A Systematic Review and Meta-analysis of Randomized Clinical Trials on the Prevention and Treatment of Pouchitis after Ileoanal Pouch Anastomosis.J Gastrointest Surg2023https://conductscience.org/library/papers/37815701PubMed
37007752Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology.Prz Gastroenterol2023https://conductscience.org/library/papers/37007752PubMed
36777755#MondayNightIBD: Management of Chronic #Pouchitis.Crohns Colitis 3602020https://conductscience.org/library/papers/36777755PubMed
36171809Acute pouchitis: the condition that time forgot about.Ther Adv Gastroenterol2022https://conductscience.org/library/papers/36171809PubMed
34868349α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis.Ther Adv Gastroenterol2021https://conductscience.org/library/papers/34868349PubMed
34335051Pouchitis: Clinical Features, Diagnosis, and Treatment.Int J Gen Med2021https://conductscience.org/library/papers/34335051PubMed
34249146Medical treatment of pouchitis: a guide for the clinician.Ther Adv Gastroenterol2021https://conductscience.org/library/papers/34249146PubMed
34180986Disease Activity Indices for Pouchitis: A Systematic Review.Inflamm Bowel Dis2022https://conductscience.org/library/papers/34180986PubMed
34163205Chronic Antibiotic-Refractory Pouchitis: Management Challenges.Clin Exp Gastroenterol2021https://conductscience.org/library/papers/34163205PubMed
33162735Inflammatory bowel disease and pregnancy: fertility, complications and treatment.Ann Gastroenterol2020https://conductscience.org/library/papers/33162735PubMed

See all 43 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17567869

GET https://conductscience.org/api/papers/v1/17567869/cited_by?page=2